Blocking periostin isoforms with antisense oligonucleotides and antibodies markedly reduced osteoblast-specific-differentiation markers, suggesting a role in osteoblast differentiation.
Does blocking periostin isoforms reduce osteoblast differentiation in MC3T3-E1 cells?
Periostin isoforms, including periostin-like-factor (PLF), play a role in osteoblast differentiation.
Periostin was originally identified in MC3T3-E1 osteoblast-like cells. We have identified an isoform of periostin referred to as periostin-like-factor (PLF). It is homologous to other proteins such as fasciclin I (fas I), MPB70, betaIG-H3, and Algal-CAMs. All of these proteins are implicated in regulating cell adhesion. PLF and the other isoforms of periostin differ in their C-terminal sequences. PLF and periostin differ in two specific regions, between 673 and 699 amino acids (aa) and 785-812 aa. Periostin isoforms are expressed in vivo and in vitro during the stages of osteoblast differentiation and maturation. Their mRNAs are present in pre-osteoblast cells as detected by in situ hybridization, and the proteins are between 86 and 93 kD in size as determined by Western blot analysis. Antisense oligonucleotides and antibodies directed against the isoforms of periostin were used to block the activity of these proteins. In both cases, the levels of osteoblast-specific-differentiation markers were markedly reduced suggesting a role for these proteins in osteoblast differentiation.
Litvin et al. (Mon,) reported a other. Antisense oligonucleotides and antibodies directed against periostin isoforms was evaluated on Levels of osteoblast-specific-differentiation markers. Blocking periostin isoforms with antisense oligonucleotides and antibodies markedly reduced osteoblast-specific-differentiation markers, suggesting a role in osteoblast differentiation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: